• Revenue up 4% to $6.64m
• EBIT up 19% to $1.107m
• EBITDA up 15% to $1.518m
• Dividend increased 33% to 2 cents per share

Cryosite Limited has reported a strong financial performance in the first half of the 2025 financial year, with revenue from ordinary activities increasing by 4% to $6.64 million, and earnings before interest and tax (EBIT) rising by 19% to $1.107 million. Earnings before interest, tax, depreciation and amortisation (EBITDA) also increased by 15% to $1.518 million, demonstrating the company's ability to scale its business efficiently. While net profit after tax (NPAT) decreased by 1% to $838,000 due to an increase in income tax expenses, the directors are extremely pleased with the positive momentum and the company's positioning for further growth in 2025. Cryosite's core business activities, including clinical trials and biological services logistics, as well as cord blood and tissue storage, have all contributed to the strong performance. The company has also made significant investments in its facilities, systems, and staff to support its growth strategy. Additionally, Cryosite returned 5 cents per share ($2.4 million) to shareholders in February 2024 via a capital reduction, and the Board declared a final unfranked dividend of 2 cents per share for the 2024 financial year, a 33% increase from the previous year.

Cryosite is poised for further growth in 2025 as the company builds upon the investments made to date in its people, processes, and facilities. The company's stability in a changing industry landscape reflects effective strategic planning and execution, and the ability to maintain a steady course while adapting to the evolving needs of its clients and the market.